Latest news with #SmartValueNewsletter
Business Insider
an hour ago
- Business
- Business Insider
Stifel Nicolaus Sticks to Their Buy Rating for Alkermes (ALKS)
In a report released today, Paul Matteis from Stifel Nicolaus maintained a Buy rating on Alkermes (ALKS – Research Report), with a price target of $42.00. The company's shares closed last Friday at $29.09. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Matteis is a 3-star analyst with an average return of 1.2% and a 41.20% success rate. Matteis covers the Healthcare sector, focusing on stocks such as Alkermes, Neurocrine, and uniQure. In addition to Stifel Nicolaus, Alkermes also received a Buy from UBS's Ashwani Verma in a report issued on June 17. However, on June 10, RBC Capital maintained a Hold rating on Alkermes (NASDAQ: ALKS).
Business Insider
an hour ago
- Business
- Business Insider
Ventyx Biosciences (VTYX) Gets a Hold from Stifel Nicolaus
In a report released today, from Stifel Nicolaus maintained a Hold rating on Ventyx Biosciences (VTYX – Research Report), with a price target of $2.00. The company's shares closed last Friday at $2.26. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter In addition to Stifel Nicolaus, Ventyx Biosciences also received a Hold from Morgan Stanley's Vikram Purohit in a report issued on June 17. However, on June 18, Wells Fargo maintained a Buy rating on Ventyx Biosciences (NASDAQ: VTYX). VTYX market cap is currently $160.8M and has a P/E ratio of -1.29.
Business Insider
an hour ago
- Business
- Business Insider
Stifel Nicolaus Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)
In a report released today, Alex Thompson CFA from Stifel Nicolaus maintained a Buy rating on Dianthus Therapeutics (DNTH – Research Report), with a price target of $52.00. The company's shares closed last Friday at $16.86. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Thompson CFA covers the Healthcare sector, focusing on stocks such as Kymera Therapeutics, Travere Therapeutics, and Viridian Therapeutics. According to TipRanks, Thompson CFA has an average return of -3.4% and a 43.20% success rate on recommended stocks. Dianthus Therapeutics has an analyst consensus of Strong Buy, with a price target consensus of $46.75, which is a 177.37% upside from current levels. In a report released on June 18, LifeSci Capital also maintained a Buy rating on the stock with a $45.00 price target. The company has a one-year high of $32.27 and a one-year low of $13.37. Currently, Dianthus Therapeutics has an average volume of 319.1K.
Business Insider
an hour ago
- Business
- Business Insider
Paladin Energy Ltd (PALAF) Receives a Hold from Jefferies
Jefferies analyst Daniel Roden maintained a Hold rating on Paladin Energy Ltd (PALAF – Research Report) on June 19 and set a price target of A$8.50. The company's shares closed last Friday at $4.70. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Roden is an analyst with an average return of -3.4% and a 32.14% success rate. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Paladin Energy Ltd with a $5.46 average price target. The company has a one-year high of $10.53 and a one-year low of $2.33. Currently, Paladin Energy Ltd has an average volume of 162.2K.
Business Insider
4 hours ago
- Business
- Business Insider
‘Still Not a Bargain,' Says Top Investor About Nike Stock
'Just Do It,' goes the motto that Nike (NYSE:NKE) made a household catchphrase. With its branded 'Swoosh' and world-famous spokespeople, it is no stretch to argue that Nike helped to build the premium shoe market — one that grew by leaps and bounds earlier this decade. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Indeed, the COVID years saw a major spike in Nike's footwear sales – from $23.3 billion in 2020 to over $35 billion in 2023 – though growth has been slowing of late. Last year saw footwear revenues decrease slightly, and its share price has fallen almost 40% during the past twelve months. This week, Nike will be releasing its FQ4 2025 results, and consensus estimates are not exactly bullish. Analysts are expecting total revenues of $10.7 billion – down 15% year-over-year – while a projected EPS of $0.12 would represent an 89% decrease year-over-year. One top investor known by the pseudonym Stone Fox Capital thinks that the growing competition will continue to present stiff resistance going forward. 'Nike remains overvalued despite a significant price decline, with the market underestimating downside risks and ongoing competitive pressures,' explains the 5-star investor, who is among the top 3% of TipRanks' stock pros. The biggest challenge for Nike going forward will be the growing competition, asserts Stone Fox Capital, citing On Holding and HOKA as two of the biggest threats. For instance, ONON's On Running is expected to grow revenues by 40% this year. Still, NKE is trading 'at multiples above the market,' despite forecasts of stagnating growth going forward. Stone Fox Capital spots quite a disconnect – one that the market has yet to take fully into account. 'Nike should be viewed based on the readily available data of a massive athletic footwear company that hasn't grown in years facing immense competition,' adds Stone Fox Capital. Stone Fox Capital is urging investors to pay attention to upcoming guidance for the next quarter, which the investor predicts will be a 'horrible' forecast. Needless to say, Stone Fox Capital does not believe that 'Just Do It' is good advice for would-be investors at present. 'The stock might be down substantially from the all-time highs a few years ago, but Nike isn't actually trading like the business is under pressure,' concludes Stone Fox Capital, who rates NKE a Sell. (To watch Stone Fox Capital's track record, click here) Wall Street is overall positive when it comes to Nike, though not overwhelmingly. With 12 Buy and 11 Hold ratings, NKE is a consensus Moderate Buy. Its 12-month average price target of $71.24 has an upside of ~19%. (See NKE stock forecast) To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
